Neurocrine Biosciences Announces FDA Approval of Ingrezza (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington ' s Disease

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved Ingrezza® (valbenazine) capsules for the treatment of adults with chorea associated...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news